Early onset of SARS-CoV-2 antibodies after first dose of BNT162b2: correlation with age, gender and BMI
Autor: | Fabrizio Ensoli, Flaminia Campo, Fulvia Pimpinelli, Antonello Vidiri, Armando De Virgilio, Federico De Marco, Branka Vujovic, Fabrizio Petrone, Silvia Moretto, Chiara Mandoj, Raul Pellini, Elva Abril, Ornella Di Bella, Martina Pontone, Jacopo Zocchi, Enea Gino Di Domenico, Simona di Martino, Gennaro Ciliberto, Diana Giannarelli, Giovanni Blandino, Laura Conti, Aldo Morrone, Barbara Pichi, Aldo Venuti, Francesco Mazzola, Valentina Manciocco, Paolo Marchesi, Gerardo Petruzzi, Giulia Piaggio |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2021 |
Předmět: |
0301 basic medicine
obesity Immunology Physiology Correlation 03 medical and health sciences 0302 clinical medicine Immune system vaccine Drug Discovery Medicine antibodies Pharmacology (medical) 030212 general & internal medicine Pharmacology biology business.industry SARS-CoV-2 Brief Report COVID-19 medicine.disease Obesity serum titer Clinical trial Titer 030104 developmental biology Infectious Diseases biology.protein Antibody Underweight medicine.symptom business Body mass index |
Zdroj: | Vaccines Vaccines, Vol 9, Iss 685, p 685 (2021) |
Popis: | Background: The first goal of the study was to analyse the antibody titre 21 days after the first dose of the BNT162b2 vaccine in a group of 252 healthcare workers (HCW). The second goal was to analyse how the antibody titre changes in correlation with age, gender and body mass index (BMI). Methods: Participants had a nasopharyngeal swab for SARS-CoV-2 and were assessed for the presence of SARS-CoV-2 antibodies at baseline and 21 days after the BNT162b2 priming dose. Results: First dose of BNT162b2 activated immune responses in 98% of the participants. Five HWC had no increase in antibody titre 21 days after the first dose. Antibody titre was greater in young (p = 0.002; 56 p = 0.001). Higher antibody levels were detected in underweight vs. pre-obesity group (p = 0.026) and in normal-weight vs. pre-obesity group (p = 0.007). This association was confirmed after adjusting for age (p = 0.0001) and gender (p = 0.00001). Conclusions: Our study demonstrates that a single dose of BNT162b2 activates the immune response, and being young and normal-weight correlate positively with this response. Larger specifically designed clinical trials are needed to validate these results. |
Databáze: | OpenAIRE |
Externí odkaz: |